Pfizer Inc. news

   Watch this stock
Showing stories 1 - 10 of about 182   

Articles published

PFE 29.84 +0.35 (1.19%)
price chart
Pfizer Inc.'s Earnings: Emerging Market Growth and Patent Expirations Square Off
Having lost Lipitor, Viagra, and a number of other key therapies to generic competition in recent years, CEO Ian Read and Pfizer have made it clear that the company plans to grow its business organically and through acquisitions in order to get past ...
Pfizer CEO: Still exploring tax-inversion deal  Philly.com
Pfizer Inc Edges Out Earnings Estimates  ValueWalk
Related articles »  
Pfizer beats sales and profit forecasts, mum on future deals
(Reuters) - Pfizer Inc (PFE.N) reported stronger-than-expected quarterly results, helped by growing sales of its cancer drugs and demand for its medicines in emerging markets, but did not signal any acquisition plans following its recent failed efforts ...
Pfizer (PFE) Stock Falls After Dropping Pain Drug
NEW YORK (TheStreet) -- Shares of Pfizer Inc. (PFE) are down by 0.21% to $29.05 after the pharmaceutical company notified Pain Therapeutics, Inc. (PTIE) that it has decided to discontinue its agreement to develop and commercialize Remoxy ...
Pfizer To Discontinue Development Of Remoxy Extended-Release Capsules CII  RTT News
DURECT Provides Update on REMOXY� and POSIDUR� Programs  MarketWatch
Related articles »  
Can This 1 Breast Cancer Drug Turn Pfizer Inc. Into a Growth Stock?
Big Pharma is undergoing a radical face-lift due to the avalanche of top-selling drugs losing patent protection. The consequences of the aptly named "patent cliff" have been widespread and immense in scope.
Pfizers Trumenba Gains Accelerated Approval in the U.S.
Pfizer Inc.'s (PFE - Analyst Report) Trumenba (meningococcal group B vaccine) received accelerated approval from the FDA for the active immunization of people aged 10 - 25 years for the prevention of invasive disease caused by Neisseria meningitidis ...
UPDATE 2-Pfizer meningitis vaccine wins US approval  Reuters
Related articles »  
Stocks to Watch: Pfizer, DuPont, Whirlpool
Among the companies with shares expected to actively trade in Tuesday's session are Pfizer Inc., DuPont Co. and Whirlpool Corp.
Related articles »  
Pfizer Approves $11B Stock Repurchase Plan
Pfizer Inc. is the world's second-largest drugmaker, and its products include the vaccine Prevnar and pain and fibromyalgia treatment Lyrica.
Pfizer Stock Buyback Plan Just Too Large to Ignore � It Is on Viagra  24/7 Wall St.
Pfizer Announces It Will Buy Back $11 Billion in Shares  Bloomberg
Related articles »  
The Most Important Number You Need to Know Before Buying Pfizer Inc. Stock
Every company has one number that defines its success more than any other. For Pfizer (NYSE: PFE ) , the world's largest pharmaceutical company, that number is... $10.7 billion. Pfizer has four blockbuster drugs coming off-patent in the United States ...
Tax rules won't stop Pfizer from bidding U.S. goodbye, CEO says
NEW YORK - The U.S. attempt to stop companies from leaving the country for tax reasons won't stop Pfizer Inc., which is still considering a deal to move America's biggest drugmaker abroad, Chief Executive Officer Ian Read said Tuesday.
Should Pfizer Inc. Buy This Surprisingly Competitive Biotech Stock?
PCSK9 inhibitors, and their potential sales, have garnered a lot of interest from investors Pfizer's (NYSE: PFE ) Lipitor peaked at well over $10 billion in annual sales.